Srinivasa Reddy Bonam | Immunology | Young Scientist Award

Published on by Young Scientists Awards

Dr. Srinivasa Reddy Bonam | Immunology | Young Scientist Award

Senior Scientist | Indian Institute of Chemical Technology | India

Dr. Srinivasa Reddy Bonam is a distinguished scientist specializing in immunology, vaccine development, and pharmacology, with a significant research impact demonstrated by over 4,892 citations from 4,654 documents and an h-index of 29. He currently serves as an Assistant Professor at the Academy of Scientific and Innovative Research (AcSIR) and Senior Scientist at CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad, India. His extensive research experience spans advanced vaccine design, mRNA therapeutics, immunomodulators, and host-pathogen interactions. Dr. Bonam completed his Ph.D. at CSIR-IICT, Hyderabad, focusing on the immunopharmacological evaluation of novel glycopeptides and glycolipids as vaccine adjuvants and immunomodulators. His doctoral research led to the identification of multiple lead adjuvant candidates, with one licensed by Bharat Biotech International Ltd for emerging vaccines. After his Ph.D., he pursued postdoctoral research in Europe and the USA, contributing to the development of therapeutic peptides for autoimmune diseases at the University of Strasbourg, innovative immune regulation mechanisms in fungal infections and COVID-19 at INSERM Paris, and designing novel mRNA vaccines at the University of Texas Medical Branch (UTMB) in collaboration with Prof. Drew Weissman’s lab. Dr. Bonam has received honors including the Marie Curie Fellowship (self-denied), Outstanding Reviewer Awards from MDPI journals, and the Distinguished Alumni Award from CIPS. He serves as Editor-in-Chief of Advances in Pharmacology and Pharmacy, editorial board member of multiple journals, and peer reviewer for over 90 scientific journals. His pioneering contributions include patents on novel vaccine adjuvants and the development of Uttroside, a saponin-based vaccine adjuvant licensed to Bharat Biotech International Ltd. Driven by a commitment to next-generation vaccines and therapeutic strategies, Dr. Bonam continues to address emerging global health challenges through his high-impact research.

Profile: Scopus

Featured Publications

  1. Alameh, M.-G., Semon, A., Hu, H., Bonam, S. R., Maslanka, J. R., Weissman, D., & Zackular, J. P. (2024). A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection. Science, 386(6717), 69–75.

  1. Bonam, S. R., Hazell, N. C., Mathew, M. J., Liang, Y., Zhang, X., Wei, Z., Alameh, M.-G., Weissman, D., & Hu, H. (2024). Innate and adaptive immune parameters following mRNA vaccination in mice. Vaccines, 12(5), 543.

  1. Ye, Z., Bonam, S. R., McKay, L. G. A., Plante, J. A., Walker, J., Zhao, Y., Huang, C., … Hu, H. (2023). Monovalent SARS-CoV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proceedings of the National Academy of Sciences, 120(52), e2311752120.

  2. Bonam, S. R., Platenburg, P. P., & Bayry, J. (2022). Retrospective analysis on the immunopotentiating mechanism of an emulsion-based vaccine adjuvant on human antigen-presenting cells. Frontiers in Immunology, 13, 7738.

  3. Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Bonam, S. R., … Hu, H. (2022). Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Science Translational Medicine, 14, eabq1945.

Muhammad Azeem | Immunology | Best Researcher Award

Published on by Young Scientists Awards

Dr. Muhammad Azeem | Immunology | Best Researcher Award

University Hospital Wuerzburg | Germany

Muhammad Azeem is a molecular immuno-oncology researcher with expertise in tumor immunology, bone disease, and drug development. Currently a postdoctoral researcher at the University Hospital Würzburg, he focuses on identifying early diagnostic markers of myeloma bone disease and exploring novel drug combinations for treatment. Azeem has a strong background in molecular biology, 3D cell culture systems, and animal modeling, integrating in vitro assays with transcriptome profiling to advance precision medicine. His academic and professional journey spans veterinary medicine, immunology, and translational oncology research, making him a versatile scientist with expertise in molecular techniques, bioinformatics, and advanced cell-based models. He has actively contributed to high-impact publications, organized scientific meetings, and collaborated with interdisciplinary teams on cutting-edge cancer research. With a strong passion for leadership and innovation, Azeem aspires to lead research teams and drive advancements in therapeutic strategies. His career demonstrates dedication to bridging fundamental science with clinical applications in oncology.

Profile

Google Scholar

Education 

Muhammad Azeem educational journey reflects his deep commitment to biomedical sciences and translational research. He earned a Doctor of Veterinary Medicine degree from the University of Veterinary and Animal Sciences in Lahore, where he developed strong foundations in animal health and disease mechanisms. He further pursued a Master’s degree in Biology from the Lahore University of Management Sciences, gaining extensive training in molecular biology, immunology, and laboratory research techniques. Building upon this, Azeem completed his PhD in Immunology at the Graduate School of Life Sciences, Julius Maximilians University of Würzburg. His doctoral work focused on immune regulation, contact hypersensitivity models, and the genetic and molecular pathways controlling T-cell responses. During his PhD, he gained hands-on expertise in transgenic mouse models, molecular cloning, protein expression, flow cytometry, and qRT-PCR. This combination of veterinary, biological, and immunological training provides him with an interdisciplinary perspective that bridges animal research, cellular modeling, and human disease studies.

Experience 

Muhammad Azeem professional experience spans veterinary research, molecular biology, and immuno-oncology. He began his career at the Veterinary Research Institute in Lahore, where he worked on serological and molecular diagnostics for diseases affecting livestock, such as brucellosis and foot-and-mouth disease, and conducted epidemiological screenings of avian species. Transitioning to academic research, he joined the University Hospital Würzburg, where he completed his doctoral studies on immune regulation and T-cell development using animal models. As a postdoctoral researcher, Azeem specializes in developing advanced 3D cell culture models for studying tumor-bone interactions and identifying early markers of myeloma bone disease. He supervises undergraduate and master’s students, manages laboratory operations, and contributes to grant writing and scientific publications. Azeem has also led collaborations involving transcriptomic profiling and RNA sequencing, combining experimental and computational expertise. His organizational skills extend to planning large-scale symposia and research meetings, reflecting a career dedicated to advancing translational cancer research.

Awards and Honors 

Muhammad Azeem has been recognized for his contributions to cancer and immunology research through multiple awards and active participation in scientific events. He won the Best Poster Prize at the Annual DGHO Meeting in Basel for his work on multiple myeloma and previously earned a Second Best Poster Award at the EUREKA International Symposium. Azeem has been invited to deliver talks and present his research at leading conferences, including the Signal Transduction Meeting, IZKF Würzburg Retreat, and Annual T-Cell Meeting. He has also presented his findings at international symposia and workshops, gaining recognition for his work on immune signaling and disease modeling. His leadership roles include organizing international scientific events such as the EUREKA Symposium, which hosted hundreds of participants, and coordinating annual meetings under the DFG μBone consortium. These achievements demonstrate his growing influence in immuno-oncology and his ability to contribute to both research excellence and scientific community engagement.

Research Focus 

Muhammad Azeem research focuses on molecular immuno-oncology, with a particular emphasis on understanding and treating myeloma bone disease. His work integrates animal models, transcriptome profiling, and advanced 3D cell culture systems to identify early diagnostic markers and test innovative therapeutic strategies. Azeem is passionate about combining in vitro and in vivo approaches to better model tumor microenvironments and explore novel drug combinations. His research interests span immune cell signaling, T-cell development, cytokine regulation, and the mechanobiology of bone-tumor interactions. He has contributed to projects investigating immune regulation in skin and bone diseases, as well as studies on cancer therapeutics and centrosome biology. His interdisciplinary expertise bridges veterinary science, molecular biology, and oncology, enabling him to approach disease modeling and drug development holistically. Azeem’s long-term vision is to lead a research group dedicated to translating basic science into clinical solutions, advancing precision medicine and immunotherapy in cancer treatment.

Publications

Title: Current insights into immunology and novel therapeutics of atopic dermatitis
Year: 2021
Citations: 89

Title: T cells control chemokine secretion by keratinocytes
Year: 2019
Citations: 35

Title: Intricate relationship between adaptive and innate immune system in allergic contact dermatitis
Year: 2020
Citations: 27

Title: A 3D bioreactor model to study osteocyte differentiation and mechanobiology under perfusion and compressive mechanical loading
Year: 2024
Citations: 5

Title: NFAT5 controls the Integrity of Epidermis
Year: 2021
Citations: 5

Conclusion

Muhammad Azeem is a highly deserving candidate for the Best Researcher Award, with a strong foundation of impactful publications, innovative research methodologies, and demonstrated leadership in both research and scientific event organization. His contributions to understanding myeloma pathogenesis, immune regulation, and therapeutic strategies position him as a rising star in immuno-oncology. With further emphasis on independent research leadership and broader collaborations, he is poised to become a leading figure in his field.